Fundraising Fox

Granite Bio

Basel, CH · Founded 2021 · 26 employees on LinkedIn · 5 known investors

Find your way into Granite Bio

297 people in our graph share verified history with the Granite Bio team — schools, employers, funds. One of them is your warm intro.

Tom Hulmeunlockedknows Patrick Loustau · together at Harvard Business School (overlapped)
×10knows the team · via Harvard Business School
knows the team · via Novo Nordisk

Granite Bio develops first-in-class therapeutic antibodies targeting inflammation, autoimmunity, and fibrosis for patients lacking effective treatment options. The company is based in Basel, Switzerland, with a pipeline including Minokitug for autoimmune inflammation and GRT-002 for allergy and itch conditions.

BiotechMedical Devices

Founders & leadership

PLPatrick Loustau
Patrick LoustauinPresident and Chief Executive OfficerPatrick Loustau previously served as chief business officer at Amolyt Pharma, which was acquired by Alexion, AstraZeneca Rare Disease in 2024, and as interim CEO of Zumbro Discovery and president of Zafgen. Earlier in his career he was SVP of global commercialization for cardiovascular and metabolics at Bristol-Myers Squibb in Princeton, New Jersey.

Investors · 5

Novartis Venture Fund✓ verifiedBasel · $5M – $25M
Sanofi Ventures✓ verifiedCambridge · $5M
Forbion✓ verifiedNaarden
Versant Ventures✓ verifiedSan Francisco · $250K – $5M

Also in the syndicate · 1

Novartis Venturelead

Funding

SEC filings, press & company announcements

$30M disclosed across 1 round · 2025

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Granite Bio Debuts with USD 100m of Capital - VISCHERvischer.com · Jan 2026Granite Bio Debuts With $100 Million of Capital - BioSpacebiospace.com · Nov 2025Granite Bio secures $100m funding to target autoimmune diseasesworldpharmaceuticals.net · Apr 2025Granite Bio secures $100m in funding for new antibodiespharmaceutical-technology.com · Apr 2025Switzerland: Granite Bio emerges from stealth with US$100m in funding - Investors in Healthcareinvestorsinhealthcare.com · Apr 2025Granite Bio makes $100m debut, and other bio financingsground.news · Apr 2025Granite Bio Debuts With $100 Million of Capitalbusinesswire.com · Apr 2025Granite Bio Raises $100M in Fundingfinsmes.com · Apr 2025

Frequently asked questions

What does Granite Bio do?
Granite Bio develops first-in-class therapeutic antibodies targeting inflammation, autoimmunity, and fibrosis for patients lacking effective treatment options. The company is based in Basel, Switzerland, with a pipeline including Minokitug for autoimmune inflammation and GRT-002 for allergy and itch conditions.
Who are Granite Bio's investors?
Granite Bio's investors include Novartis Venture Fund, Sanofi Ventures, Forbion, Versant Ventures.
How much funding has Granite Bio raised?
Granite Bio has disclosed $30M raised across 1 round.
Where is Granite Bio headquartered?
Granite Bio is headquartered in Basel, CH.